HDCN Article Review/Hyperlink

Packer M

ACC Press Release: Beta blocker reduces hospitalizations in patients with the most advances chronic heart failure

Am Coll Cardiol PR (Mar) 21:Web, 2001

The following press release was issued by the American College of Cardiology concerning a paper presented at the March 2001 Annual Meeting:

(ORLANDO, FLA.)_Treatment with the beta blocker carvedilol significantly reduced the risk of hospitalization in patients with the most advanced form of chronic heart failure in the "Carvedilol Prospective Randomized Cumulative Survival" trial (COPERNICUS).

COPERNICUS investigators last year reported that carvedilol was associated with a significant 35 percent decline in the risk of death in their patients with such advanced, so-called New York Heart Association class IV heart failure. But, in addition, "We found a rather dramatic reduction in the risk of hospitalization, which was true regardless of whether we looked at hospitalization for any reason, for only heart failure or for any other cardiovascular cause," said Dr. Milton Packer, of Columbia University College of Physicians and Surgeons, New York City.

COPERNICUS patients had the most advanced stable heart failure ever studied in a beta blocker trial, Dr. Packer observed. He is scheduled to present the trial's results on hospitalizations, clinical outcomes, and drug safety at 9 a.m. on Tuesday, March 20, at the American College of Cardiology 50th Annual Scientific Session in Orlando, Fla.
         Related Folders:

Return to Home
Page